Skip to main content

Understanding your diagnosis | ALT

Atypical Lipomatous Tumour: What Does the Diagnosis Mean?

A guide to the words in your report and the decisions to discuss with your specialist.

Open cream paper folder with blank sheets, navy shapes and a leafy branch in a vase.

An atypical lipomatous tumour, or ALT, is a fatty tumour with abnormal cells. It can resemble an ordinary lipoma, so the distinction sometimes needs detailed examination of tissue and molecular testing.[3]

On this page

This article focuses on ALT in an arm, leg or the trunk wall. The exact wording of your report and the tumour's location are the starting points for the discussion.

Why does my report also say well-differentiated liposarcoma?

ALT and well-differentiated liposarcoma describe the same pathological entity. The name often reflects where it is growing. ALT is commonly used for a limb tumour that can be removed. Well-differentiated liposarcoma is often used for deep sites such as the retroperitoneum, behind the abdominal organs, where complete removal is more difficult and recurrence is a greater concern. Advice about an ALT in the thigh cannot simply be applied to that setting.[1]

Local recurrence

An ALT can return in the area where it was removed. This is different from metastasis, which means spread to another part of the body. Pure ALT has metastatic potential only if dedifferentiation occurs.[2]

Dedifferentiation

This means a component has changed into a different, more aggressive sarcoma. It may be present when the tumour is first diagnosed or appear later. Its presence changes the diagnosis and treatment discussion.[4]

What do MRI and MDM2 testing tell us?

MRI shows the tumour's size, depth and internal structure. Thick internal bands, nodules and areas that enhance after contrast can raise suspicion for ALT. There is overlap with lipomas, however. These findings help the team assess the lump; they are not a checklist you can use to diagnose yourself from a scan report.[3]

The pathologist examines the tissue and may test for extra copies of a gene called MDM2. A test called FISH can detect this amplification. It is useful in distinguishing ALT from some benign fatty tumours, but MDM2 amplification also occurs in other tumour types. The result has to fit the microscopic findings. Not every fatty lump needs this test.[4]

The useful distinction in your own report is between a diagnosis already established and one still awaiting confirmation. The team should explain which tests are still pending and how you will receive the final result.

What is the aim of ALT surgery?

For a limb ALT, the surgeon weighs tumour removal against the function of nearby muscles, nerves and blood vessels. Removing a wide rim of normal tissue can sometimes cause substantial harm. A planned marginal excision, following the tumour's boundary, may therefore be appropriate. The decision depends on the anatomy and the specialist team's assessment.[5]

A microscopic positive margin after a planned marginal excision does not automatically require another, wider operation. The team needs to consider what was removed and whether tumour was knowingly left behind. One word in the pathology report cannot settle that decision.[5]

Can monitoring be considered instead?

Surveillance may be considered for selected patients, particularly when symptoms are minimal and surgery has disadvantages. Evidence from a small, selected group does not establish long-term safety for everyone. Monitoring needs a plan for reassessment and for investigating concerning changes.[6]

More about the evidence

The 2026 study was retrospective. It examined adults managed with surveillance and surgery, and the surveillance group had limited follow-up.[6]

Follow-up and returning to the team

ALT can recur many years after treatment. Follow-up arrangements differ, and evidence does not establish one scan schedule for every peripheral ALT. Your follow-up plan should include whom to contact about a new swelling or concerns near the operated area, especially when routine visits become less frequent or end.[2]

Four questions for your next appointment

  • What does the complete pathology report say, including any mention of dedifferentiation?
  • How does the tumour's location affect my options?
  • What are the reasons for recommending surgery or surveillance in my case?
  • What follow-up and contact arrangements should I keep?

Frequently Asked Questions

Is an atypical lipomatous tumour the same as a lipoma?

No. Both can contain mature fat, but an atypical lipomatous tumour has abnormal cells and characteristic molecular changes. Imaging and examination of tissue help distinguish them; appearance alone does not always settle the diagnosis. [3]

Does the word liposarcoma mean this tumour has spread?

No. Pure ALT does not have metastatic potential unless a dedifferentiated component develops. The report needs to be read alongside the tumour's site and the complete pathology findings. A diagnosis containing the word liposarcoma is not, by itself, evidence of spread. [2]

What does MDM2 amplification mean?

It means extra copies of the MDM2 gene were found in the tumour cells. This can help identify ALT, but also occurs in other tumours. The pathologist interprets it with the tissue appearance and clinical setting. [4]

Can an atypical lipomatous tumour return years after surgery?

Yes. Peripheral ALT can recur locally after a long interval. Ask for a follow-up plan and a clear route back to the specialist team if a new lump or other concerning change develops near the operation site. [2]

Your consultation

Understanding your atypical lipomatous tumour report

To discuss the wording of an atypical lipomatous tumour report, you can book a consultation with Dr. Vishnu Baburaj at Aster MIMS Kannur.

Share this guide

Know someone who might find this helpful?

Pass this guide on to a friend or family member.

Dr. Vishnu Baburaj · Patient guides

The evidence behind this article

  1. Hayes AJ, Nixon IF, Strauss DC, et al. UK guidelines for the management of soft tissue sarcomas. British Journal of Cancer. 2025;132:11-31. doi:10.1038/s41416-024-02674-y. Published online 11 May 2024; lipomas and atypical lipomatous tumours section. Back to: text 1
  2. Kalimuthu SN, Tilley C, Forbes G, et al. Clinical outcome in patients with peripherally-sited atypical lipomatous tumours and dedifferentiated liposarcoma. Journal of Pathology: Clinical Research. 2015;1:106-112. doi:10.1002/cjp2.12. Back to: text 1, text 2, FAQ 2, FAQ 4
  3. Knebel C, Neumann J, Schwaiger BJ, et al. Differentiating atypical lipomatous tumors from lipomas with magnetic resonance imaging: a comparison with MDM2 gene amplification status. BMC Cancer. 2019;19:309. doi:10.1186/s12885-019-5524-5. Back to: text 1, text 2, FAQ 1
  4. Sciot R. MDM2 Amplified Sarcomas: A Literature Review. Diagnostics. 2021;11(3):496. doi:10.3390/diagnostics11030496. Back to: text 1, text 2, FAQ 3
  5. Rauh J, Klein A, Baur-Melnyk A, et al. The role of surgical margins in atypical Lipomatous Tumours of the extremities. BMC Musculoskeletal Disorders. 2018;19:152. doi:10.1186/s12891-018-2053-3. Back to: text 1, text 2
  6. Hakkesteegt SN, Shapiro J, Wunder JS, et al. Clinical Course and Dedifferentiation of Atypical Lipomatous Tumors: A Retrospective Analysis of Surveillance and Surgical Management. Annals of Surgical Oncology. 2026;33:7616-7624. doi:10.1245/s10434-026-19751-6. Back to: text 1, text 2

Medically reviewed by Dr. Vishnu Baburaj, MS Ortho (PGI Chandigarh), MRCS (UK) · Last reviewed

This article is for educational purposes and does not replace a medical consultation. For personalised advice, book an appointment at Aster MIMS Kannur.

WhatsApp Us Request an appointment